Advertisement

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)

Published:August 06, 2019DOI:https://doi.org/10.1016/j.clgc.2019.07.017

      Abstract

      Background

      The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P).

      Patients and Methods

      This was a phase IV, prospective, open-label, multicenter, real-world study. Patients were prescribed ENZA or AA+P at the treating physician’s discretion. Computerized tests of 4 cognitive domains (Cogstate), patient-reported outcomes (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-30], Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue], Functional Assessment of Cancer Therapy-Cognitive Function [FACT-Cog]), and patient/caregiver surveys were assessed at baseline and 2 months. Safety data were collected.

      Results

      Of 100 treated patients, 92 were evaluable (46/arm). Baseline characteristics were similar, with mild cognitive impairment observed in ∼20% of patients. The FACIT-Fatigue demonstrated a statistically significant worsening from baseline of −4.00 (95% confidence interval, −6.61 to −1.39) for ENZA compared with AA+P, −0.01 (95% confidence interval, −2.40 to 2.38). Overall, more adverse events (AEs) and more AEs of fatigue were reported with ENZA versus AA+P (52% vs. 36% and 26% vs. 8%, respectively). Grade 3/4 AEs were similar (4% vs. 6%). Unique neuropsychiatric AEs reported with ENZA included amnesia, cognitive disorders, memory impairment, and confusional state; those for AA+P included cerebrovascular accident, presyncope, and spinal cord compression. Clinically meaningful cognitive decline was seen in 4 patients on ENZA versus 1 patient on AA+P. However, the overall mean changes from baseline for the Cogstate tests, the EORTC QLQ-C30, and the FACT-Cog assessment were similar and showed no meaningful change. Caregiver survey responses noted more fatigue with ENZA and more moodiness with AA+P compared with patient responses.

      Conclusions

      Although baseline values were similar, more fatigue and neurocognitive differences were observed with ENZA compared with AA+P.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Xtandi [prescribing information]. Astellas Pharma US, Inc, Northbrook, IL2017
      2. Zytiga [prescribing information]. Janssen Biotech, Inc, Horsham, PA2018
        • de Bono J.S.
        • Logothetis C.J.
        • Molina A.
        • et al.
        • COU-AA-301 Investigators
        Abiraterone and increased survival in metastatic prostate cancer.
        N Engl J Med. 2011; 364: 1995-2005
        • Fizazi K.
        • Scher H.I.
        • Molina A.
        • et al.
        • COU-AA-301 Investigators
        Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
        Lancet Oncol. 2012; 13: 983-992
        • Ryan C.J.
        • Smith M.R.
        • de Bono J.S.
        • et al.
        • COU-AA-302 Investigators
        Abiraterone in metastatic prostate cancer without previous chemotherapy.
        N Engl J Med. 2013; 368: 138-148
        • Ryan C.J.
        • Smith M.R.
        • Fizazi K.
        • et al.
        • COU-AA-302 Investigators
        Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
        Lancet Oncol. 2015; 16: 152-160
        • Scher H.I.
        • Fizazi K.
        • Saad F.
        • et al.
        • AFFIRM Investigators
        Increased survival with enzalutamide in prostate cancer after chemotherapy.
        N Engl J Med. 2012; 367: 1187-1197
        • Beer T.M.
        • Armstrong A.J.
        • Rathkopf D.E.
        • et al.
        • PREVAIL Investigators
        Enzalutamide in metastatic prostate cancer before chemotherapy.
        N Engl J Med. 2014; 371: 424-433
        • Desax M.C.
        • Hundsberger T.
        • Rothermundt C.
        • Omlin A.
        • Gillessen S.
        Restless legs syndrome-an emerging potential side effect of enzalutamide: report of 2 cases.
        Clin Genitourin Cancer. 2015; 13: e385-e386
        • Joly F.
        • Alibhai S.M.
        • Galica J.
        • et al.
        Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
        J Urol. 2006; 176: 2443-2447
        • Campo R.A.
        • Agarwal N.
        • LaStayo P.C.
        • et al.
        Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong.
        J Cancer Surviv. 2014; 8: 60-69
        • Stasi R.
        • Abriani L.
        • Beccaglia P.
        • Terzoli E.
        • Amadori S.
        Cancer-related fatigue: evolving concepts in evaluation and treatment.
        Cancer. 2003; 98: 1786-1801
        • Wefel J.S.
        • Kesler S.R.
        • Noll K.R.
        • Schagen S.B.
        Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.
        CA Cancer J Clin. 2015; 65: 123-138
        • Mundell N.L.
        • Daly R.M.
        • Macpherson H.
        • Fraser S.F.
        Cognitive decline in prostate cancer patients undergoing ADT: a potential role for exercise training.
        Endocr Relat Cancer. 2017; 24: R145-R155
        • Sun M.
        • Cole A.P.
        • Hanna N.
        • et al.
        Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis.
        J Urol. 2018; 99: 1417-1425
        • Maruff P.
        • Thomas E.
        • Cysique L.
        • et al.
        Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex.
        Arch Clin Neuropsychol. 2009; 24: 165-178
        • Patel S.K.
        • Meier A.M.
        • Fernandez N.
        • Lo T.T.Y.
        • Moore C.
        • Delgado N.
        Convergent and criterion validity of the CogState computerized brief battery cognitive assessment in women with and without breast cancer.
        Clin Neuropsychol. 2017; 31: 1375-1386
        • Sands S.A.
        • Harel B.T.
        • Savone M.
        • et al.
        Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia.
        Support Care Cancer. 2017; 25: 449-457
        • Thiery-Vuillemin A.
        • Poulsen M.H.
        • Lagneau E.
        • et al.
        Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
        ESMO Open. 2018; 3: e000397
        • Khalaf D.
        • Zou K.
        • Struss W.J.
        • et al.
        Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: a retrospective cohort study. Poster presented at: 2018 Annual Meeting of the American Society of Clinical Oncology.
        June 2, 2018 (Chicago, IL)
        • McGinty H.L.
        • Phillips K.M.
        • Jim H.S.
        • et al.
        Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.
        Support Care Cancer. 2014; 22: 2271-2280
        • Gunlusoy B.
        • Ceylan Y.
        • Koskderelioglu A.
        • et al.
        Cognitive effects of androgen deprivation therapy in men with advanced prostate cancer.
        Urology. 2017; 103: 167-172
      3. Xtandi [Canadian product mongraph]. Markham, ON: Astellas Pharma Canada, Inc, 2015.
        (Availble at:)
        • Parimi S.
        • Eigl B.
        • Sunderland K.
        • et al.
        Effects of abiraterone and enzalutamide on cognitive impairment and depressive symptoms in patients with metastatic castration resistant prostate cancer (MCRPC). Poster presented at: 2016 Annual Meeting of the American Society of Clinical Oncology.
        June 3-7, 2016 (Chicago, IL)